Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2000 4
2001 12
2002 22
2003 34
2004 37
2005 65
2006 79
2007 76
2008 42
2009 33
2010 34
2011 37
2012 19
2013 24
2014 19
2015 20
2016 19
2017 16
2018 9
2019 12
2020 21
2021 14
2022 15
2023 6
2024 7
2025 7
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

640 results

Results by year

Filters applied: . Clear all
Page 1
Risk of cardiovascular events associated with selective COX-2 inhibitors.
Mukherjee D, Nissen SE, Topol EJ. Mukherjee D, et al. JAMA. 2001 Aug 22-29;286(8):954-9. doi: 10.1001/jama.286.8.954. JAMA. 2001. PMID: 11509060 Review.
Atherosclerosis is a process with inflammatory features and selective cyclooxygenase 2 (COX-2) inhibitors may potentially have antiatherogenic effects by virtue of inhibiting inflammation. ...The available data raise a cautionary flag about the risk …
Atherosclerosis is a process with inflammatory features and selective cyclooxygenase 2 (COX-2) inhibitors may po …
Disconnect between COX-2 selective inhibition and cardiovascular risk in preclinical models.
Koshman YE, Bielinski AL, Bird BM, Green JR, Kowalkowski KL, Lai-Zhang J, Mahalingaiah PK, Sawicki JW, Talaty NN, Wilsey AS, Zafiratos MT, Van Vleet TR. Koshman YE, et al. J Pharmacol Toxicol Methods. 2023 Mar-Apr;120:107251. doi: 10.1016/j.vascn.2023.107251. Epub 2023 Feb 13. J Pharmacol Toxicol Methods. 2023. PMID: 36792039 Clinical Trial.
RESULTS: The COX-2 binding assessment generally confirmed the COX-2 selectivity previously reported. ...CONCLUSION: Our data suggest that rofecoxib-related cardiovascular events in humans are not predicted by COX-2 potency o …
RESULTS: The COX-2 binding assessment generally confirmed the COX-2 selectivity previously reported. ...C …
Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features.
Ribeiro H, Rodrigues I, Napoleão L, Lira L, Marques D, Veríssimo M, Andrade JP, Dourado M. Ribeiro H, et al. Biomed Pharmacother. 2022 Jun;150:112958. doi: 10.1016/j.biopha.2022.112958. Epub 2022 Apr 19. Biomed Pharmacother. 2022. PMID: 35453005 Free article. Review.
From 828 articles identified, only eight met the inclusion criteria. Selective COX-2 inhibitors are associated with higher cardiovascular risk, while non-selective COX inhibitors are associated with higher gastrointestinal risk. .. …
From 828 articles identified, only eight met the inclusion criteria. Selective COX-2 inhibitors are associated with hig …
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.
Mukherjee D. Mukherjee D. Biochem Pharmacol. 2002 Mar 1;63(5):817-21. doi: 10.1016/s0006-2952(02)00842-0. Biochem Pharmacol. 2002. PMID: 11911832 Review.
Selective cyclooxygenase-2 (COX-2) inhibitors were developed as a response to the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents (NSAIDs). ...The widespread popularity of these agents mandates their prospective evaluati …
Selective cyclooxygenase-2 (COX-2) inhibitors were developed as a response to the gastrointestinal toxicity of c …
Non-steroidal anti-inflammatory drugs and the gastrointestinal tract.
Tai FWD, McAlindon ME. Tai FWD, et al. Clin Med (Lond). 2021 Mar;21(2):131-134. doi: 10.7861/clinmed.2021-0039. Clin Med (Lond). 2021. PMID: 33762373 Free PMC article.
Limiting NSAID use or co-administration with proton pump inhibitors (PPIs) reduce dyspepsia, peptic ulcer disease and rates of complications. Selective cyclo-oxygenase (COX)-2 inhibitors are as effective as adding PPIs in preventing upper and lower gas …
Limiting NSAID use or co-administration with proton pump inhibitors (PPIs) reduce dyspepsia, peptic ulcer disease and rates of compli …
COX-2 inhibitors and cardiovascular risk.
Funk CD, FitzGerald GA. Funk CD, et al. J Cardiovasc Pharmacol. 2007 Nov;50(5):470-9. doi: 10.1097/FJC.0b013e318157f72d. J Cardiovasc Pharmacol. 2007. PMID: 18030055 Review.
Placebo-controlled trials of nonsteroidal antiinflammatory drugs (NSAIDs) selective for COX-2 have revealed an enhanced risk for cardiovascular events. COX-2 inhibitors (coxibs) selectively reduce vascular prostacyclin synth …
Placebo-controlled trials of nonsteroidal antiinflammatory drugs (NSAIDs) selective for COX-2 have revealed an enhanced …
Management of patients with ulcer bleeding.
Laine L, Jensen DM. Laine L, et al. Am J Gastroenterol. 2012 Mar;107(3):345-60; quiz 361. doi: 10.1038/ajg.2011.480. Epub 2012 Feb 7. Am J Gastroenterol. 2012. PMID: 22310222 Review.
Hemodynamic status is first assessed, and resuscitation initiated as needed. Patients are risk-stratified based on features such as hemodynamic status, comorbidities, age, and laboratory tests. ...Nonsteroidal anti-inflammatory drugs (NSAIDs) are stopped; if they must be r …
Hemodynamic status is first assessed, and resuscitation initiated as needed. Patients are risk-stratified based on features such as h …
Gastrointestinal and cardiovascular adverse events associated with NSAIDs.
Domper Arnal MJ, Hijos-Mallada G, Lanas A. Domper Arnal MJ, et al. Expert Opin Drug Saf. 2022 Mar;21(3):373-384. doi: 10.1080/14740338.2021.1965988. Epub 2021 Aug 18. Expert Opin Drug Saf. 2022. PMID: 34376069
AREAS COVERED: The main GI and CV adverse events associated with NSAID use are reviewed. Risk factors and prophylactic strategies are also covered. EXPERT OPINION: COX-2 selective agents are safer to the GI tract but have a worst CV profile. ... …
AREAS COVERED: The main GI and CV adverse events associated with NSAID use are reviewed. Risk factors and prophylactic strateg …
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Stiller CO, Hjemdahl P. Stiller CO, et al. J Intern Med. 2022 Oct;292(4):557-574. doi: 10.1111/joim.13505. Epub 2022 May 31. J Intern Med. 2022. PMID: 35585779 Free article. Review.
Rofecoxib (Vioxx) was withdrawn from the market for this reason, but the equally COX-2 selective etoricoxib has replaced it in Europe but not in the United States. The "traditional" NSAID diclofenac is as COX-2 selective as celecoxib and …
Rofecoxib (Vioxx) was withdrawn from the market for this reason, but the equally COX-2 selective etoricoxib has replace …
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Strand V. Strand V. Lancet. 2007 Dec 22;370(9605):2138-51. doi: 10.1016/S0140-6736(07)61909-6. Lancet. 2007. PMID: 18156036 Review.
Cyclo-oxygenase-2 selective inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) are associated with increased risk of acute cardiovascular events. ...Mortality associated with gastrointestinal events is less frequent than with …
Cyclo-oxygenase-2 selective inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) are associated with in …
640 results